E.A. GAFAROVA¹, O.V. DANILOVA¹, V.L. BARYSHNIKOVA¹ 

¹Kazan State Medical Academy — Branch Campus of the FSBEI FPE RMACPE MOH Russia, Kazan

Contact details:

Gafarova E.A. — PhD (Medicine), Associate Professor of the Department of Obstetrics and Gynecology

Address: 36 Butlerov St., 420015 Kazan, Russian Federation, tel.: +7-917-287-44-28, e-mail: eagafarova1976@mail.ru

Cystic fibrosis (CF) is the most common autosomal recessive inherited disease affecting the respiratory tract, gastrointestinal tract, liver, pancreas, salivary and sweat glands, and reproductive system. The incidence of cystic fibrosis ranges from 1:2000 in Russia and is quite common among Europeans. For a long time, the life expectancy of patients with cystic fibrosis did not exceed 30–35 years, and therefore pregnancy and the birth of healthy children in women with cystic fibrosis were extremely rare. With the advent of effective antibacterial therapy, and then the introduction of selective modulators of cystic fibrosis receptors, these indicators improved. Data on the safe continuous use of selective cystic fibrosis receptor modulators during pregnancy are gradually accumulating worldwide. This makes us optimistic about the planning and implementation of reproductive function in women with cystic fibrosis.

Key words: cystic fibrosis, pregnancy, fertility, diabetes mellitus, pregnancy complication, selective cystic fibrosis receptor modulators.

REFERENCES

1. Kondrat’eva E.I., Kashirskaya N.Yu., Kapranova N.I. Natsional’nyy konsensus (2-e izdanie). Mukovistsidoz: opredelenie, diagnosticheskie kriterii, terapiya [National consensus (2nd edition). Cystic fibrosis: definition, diagnostic criteria, therapy]. Moscow: OOO “Kompaniya BORGES”, 2018. 356 p.
2. Mogayzel P.J., Naureckas E.T., Robinson K.A. Cystic fibrosis pulmonary guidelines. Am. J. Respir. Crit. Care Med, 2013, vol. 187, pp. 680–689.
3. Heltshe S.L., Godfrey E.M., Josephy T., Aitken M.L., Taylor-Cousar J.L. Pregnancy among cystic fibrosis women in the era of CFTR modulators. J. Cyst. Fibros, 2017, vol. 16 (6), pp. 687–694.
4. Krasovskiy S.A., Starinova M.A., Voronkova A.Yu., Amelina E.L., Kashirskaya N.Yu., Kondrat’eva E.I. et al. Registr patsientov s mukovistsidozom v Rossiyskoy Federatsii 2021 g. [Registry of patients with cystic fibrosis in the Russian Federation 2021]. Saint Petersburg: Blagotvoritel’nyy fond “Ostrova”, 2023. 81 p.
5. De Boeck K., Wilschanski M., Castellani C., Taylor C., Cuppens H., Dodge J. et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax, 2006, vol. 61, pp. 627–635.
6. Castellani C., Duff A.J.A., Bell S.C., Heijerman H.G.M., Munck A., Ratjen F. et al. ECFS best practice guidelines: the 2018 revision. J. Cyst. Fibros, 2018, vol. 17 (2), pp. 153–178.
7. Akulenko L.V., Zolotukhina T.V., Manukhin I.B. Dorodovaya profilaktika geneticheskoy patologii ploda [Antenatal prevention of fetal genetic pathology]. Moscow: GEOTAR-Media, 2013. 304 p.
8. Debray D., Narkewicz M.R., Bodewes F.A., Colombo C., Housset C., de Jonge H.R. et al. Cystic fibrosis — related liver disease: research challenges and future perspectives. J. Pediatr. Gastroenterol. Nutr, 2017, vol. 65, pp. 443–448.
9. Ciucă I.M., Pop L., Tămaş L., Tăban S. Cystic fibrosis liver disease — from diagnosis to risk factors. Rom. J. Morphol. Embryol, 2014, vol. 55 (1), pp. 91–95.
10. Terliesner N., Vogel M., Steighardt A., Gausche R., Henn C., Hentschel J. et al. Cystic-fibrosis related-diabetes (CFRD) is preceded by and associated with growth failure and deteriorating lung function. J. Pediatr. Endocrinol. Metab, 2017, vol. 34–51.
11. Polgreen P.M., Comellas A.P. Clinical phenotypes of cystic fibrosis carriers. Annu. Rev. Med, 2022, vol. 27, pp. 563–574.
12. Klimko N.N. Mikozy: diagnostika i lechenie. Rukovodstvo dlya vrachey. 3-e izd., pererab. i dop. [Mycoses: diagnostics and treatment. Manual for physicians. 3rd ed., revised and enlarged]. Moscow: Farmtek, 2017. 272 p.
13. Liu J.C. et al. What is the clinical significance of filamentous fungi positive sputum cultures in patients with cystic fibrosis? J. Cystic Fibrosis, 2013, pp. 187–193.
14. Aaron S.D., Vandemheen K.L., Freitag A., Pedder L., Cameron W., Lavoie A. et al. Treatment of Aspergillus fumigates in patients with cystic fibrosis: a randomized, placebo-controlled pilot study. PLoS One, 2012, vol. 7, p. 36077.
15. Eickmeier O., Hector A., Singh A., Hart D. Fungi in cystic fibrosis: recent findings and unresolved questions. Curr. Fungal. Infect. Rep, 2014, pp. 345–347.
16. Aris R.M., Merkel P.A., Bachrach L.K., Borowitz D.S., Boyle M.P., Elkin S.L. et al. Consensus statement: Guide to bone health and disease in cystic fibrosis. J. Clin. Endocrinol. Metabol, 2005, vol. 90 (3), pp. 1888–1896.
17. Pashkevich A.A., Kovalev V.N., Nikitina M.I. et al. Evaluation of the effectiveness of vitamin D deficiency correction in children with cystic fibrosis in St. Petersburg: results of a 12-month prospective study. Pediatr, 2018, vol. 9, no. 5, pp. 59–65 (in Russ.).
18. Hughan K.S., Daley T., Rayas M.S., Kelly A., Roe A. Female reproductive health in cystic fibrosis. J. Cyst Fibros, 2019, vol. 18 (2), pp. 95–104.
19. Goldsweig B., Kaminski B., Sidhaye A., Blackman S.M., Kelly A. Puberty in cystic fibrosis. J. Cyst. Fibros, 2019, vol. 18 (2), pp. 88–94.
20. Johannesson M., Bogdanovic N., Nordqvist A.C., Hjelte L., Schalling M. Cystic fibrosis mRNA expression in rat brain: Cerebral cortex and medial preoptic area. Neuroreport, 1997, vol. 8, pp. 535–539.
21. Fijean A.L., Chamagne M., Billon Y., Morel O., Dahlhoff S. Mucoviscidose et grossesse: impact, facteurs pronostiques et prise en charge obstétricale [Cystic fibrosis and pregnancy: Outcome, prognostic factors and obstetrical management]. Gynecol. Obstet. Fertil. Senol, 2020, vol. 48 (5), pp. 428–435.
22. Kazmerski T.M., Sawicki G.S., Miller E., Jones K.A., Abebe K.Z., Tuchman L.K. et al. Sexual and reproductive health behaviors and experiences reported by young women with cystic fibrosis. J. Cyst. Fibros, 2018, vol. 17, pp. 57–63.
23. Choi H.J., Chung Y.S., Kim H.J., Moon U.Y., Choi Y.H., van Seuningen I. et al. Signal pathway of 17beta-estradiol-induced MUC5B expression in human airway epithelial cells. Am. J. Respir. Cell Mol. Biol, 2009, vol. 40, pp. 168–178.
24. Chotirmall S.H., Smith S.G., Gunaratnam C., Cosgrove S., Dimitrov B.D., O’Neill S.J. et al. Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis. N. Engl. J. Med, 2012, vol. 366, pp. 1978–1986.
25. Zeitlin P.L. Cystic fibrosis and estrogens: a perfect storm. J. Clin. Invest, 2008, vol. 118, pp. 3841–3844.
26. Schram C.A., Stephenson A.L., Hannam T.G., Tullis E. Cystic fibrosis (cf) and ovarian reserve: A cross-sectional study examining serum anti-mullerian hormone (amh) in young women. J. Cyst. Fibros, 2015, vol. 14, pp. 398–402 (accessed on 9 December 2022).
27. Tizzano E.F., Silver M.M., Chitayat D., Benichou J.C., Buchwald M. Differential cellular expression of cystic fibrosis transmembrane regulator in human reproductive tissues. Clues for the infertility in patients with cystic fibrosis. Am. J. Pathol, 1994, vol. 144, pp. 906–914.
28. Tomaiuolo G., Rusciano G., Caserta S., Carciati A., Carnovale V., Abete P. et al. A new method to improve the clinical evaluation of cystic fibrosis patients by mucus viscoelastic properties. PLoS One, 2014, vol. 3, pp. 9 (1). e82297.
29. Jain R., Kazmerski T.M., Zuckerwise L.C., West N.E., Montemayor K., Aitken M.L. et al. Pregnancy in cystic fibrosis: Review of the literature and expert recommendations. J. Cyst. Fibros, 2022, vol. 21 (3), pp. 387–395.
30. Shteinberg M., Lulu A.B., Downey D.G., Blumenfeld Z., Rousset-Jablonski C., Perceval M. et al. Failure to conceive in women with CF is associated with pancreatic insufficiency and advancing age. J. Cyst. Fibros, 2019, vol. 18 (4), pp. 525–529.
31. Reynaud Q., Poupon-Bourdy S., Rabilloud M., Al Mufti L., Rousset Jablonski C., Lemonnier L. et al. Participating centers of the French Cystic Fibrosis Registry. Pregnancy outcome in women with cystic fibrosis-related diabetes. Acta Obstet. Gynecol. Scand, 2017, vol. 96 (10), pp. 1223–1227.
32. Esan O.B., Schlüter D.K., Phillips R., Cosgriff R., Paranjothy S., Williams D. et al. Pregnancy rates and outcomes in women with cystic fibrosis in the UK: comparisons with the general population before and after the introduction of disease-modifying treatment. BJOG, 2022, vol. 129 (5), pp. 743–751.
33. Shteinberg M., Taylor-Cousar J.L., Durieu I., Cohen-Cymberknoh M. Fertility and pregnancy in cystic fibrosis. Chest, 2021, vol. 160 (6), pp. 2051–2060.
34. Taylor-Cousar J.L., Jain R. Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation. J. Cyst. Fibros, 2021, vol. 20 (3), pp. 402–406.
35. Nash E.F., Middleton P.G., Taylor-Cousar J.L., Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators — an international survey. J. Cyst. Fibros, 2020, vol. 19, pp. 521–526.
36. Kaminski R., Nazareth D. A successful uncomplicated CF pregnancy while remaining on Ivacaftor. J. Cyst. Fibros, 2016, vol. 15 (1), pp. 133–134.
37. Patel E.M., Swamy G.K., Heine R.P., Kuller J.A., James A.H., Grotegut C.A. Medical and obstetric complications among pregnant women with cystic fibrosis. Am. J. Obstet. Gynecol, 2015, vol. 212 (1), pp. 98.e1-9.
38. Jelin A.C., Sharshiner R., Caughey A.B. Maternal co-morbidities and neonatal outcomes associated with cystic fibrosis. J. Matern. Fetal. Neonatal. Med, 2017, vol. 30 (1), pp. 4–7.
39. Carpino E.A., Fowler R.E., Uluer A.Z., Sawicki G.S Acute clinical outcomes following participation in short-term CFTR modulator trials in adults with cystic fibrosis: a retrospective chart review. Pediatr. Pulmonol, 2018, vol. 53, pp. 260–261.
40. Trimble A.T., Donaldson S.H. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation. J. Cyst. Fibros, 2018, vol. 17, pp. 13–16.
41. Vekaria S., Popowicz N., White S.W., Mulrennan S. To be or not to be on CFTR modulators during pregnancy: risks to be considered. J. Cyst. Fibros, 2020, vol. 19, pp. 7–8.
42. Trimble A., McKinzie C., Terrell M., Stringer E., Esther Jr.C.R. Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding. J. Cyst. Fibros, 2018, vol. 17, pp. 779–782.
43. Mainz J.G., Michl R.K., Beiersdorf N., Lorenz M., Schneider U., Groten T. et al. Successful pregnancy of a patient with cystic fibrosis genotype F508del/ F508del and progressed pulmonary destruction on lumacaftor/ivacaftor. Klin. Padiatr, 2019, vol. 231 (5), pp. 271–273.
44. Amelina E.L., Shuginin I.O., Chernyak A.V. Cystic fibrosis and pregnancy. Consilium Medicum, 2009, vol. 11, no. 11, pp. 21–24 (in Russ.).
45. Montemayor K., Kazmerski T.M., Riekert K.A., Psoter K.J., Jain R., Taylor-Cousar J.L. et al. Clinician attitudes and practices on pregnancy planning and care in cystic fibrosis. J. Cyst. Fibros, 2023, vol. 22 (2), pp. 201–206.
46. Montemayor K., Tullis E., Jain R., Taylor-Cousar J.L. Management of pregnancy in cystic fibrosis. Breathe, 2022, vol. 18, p. 220005.
47. Moran A., Brunzell C., Cohen R.C., Katz M., Marshall B.C., Onady G. et al. Clinical care guidelines for cystic fibrosis-related diabetes: A position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care, 2010, vol. 33, pp. 2697–2708 (accessed on 9 December 2022).
48. Dos Santos T.F., Rabassa A., Aljure O., Zbeidy R. Perioperative management and preemptive ECMO cannulation of a parturient with cystic fibrosis undergoing cesarean delivery. Case Rep. Anesthesiol, 2020, p. 8814729 (accessed on 7 February 2023).